Dyne Therapeutics, Inc. granted inducement equity awards to 6 newly hired employees as a material inducement for their acceptance of employment. The awards were issued in accordance with Nasdaq Listing Rule 5635(c)(4). The grants included non-statutory stock options to purchase an aggregate of 126,000 shares of common stock and restricted stock units covering 40,100 shares.

The stock options have a ten-year term and an exercise price equal to the closing price of Dyne's common stock on The Nasdaq Global Select Market on June 16, 2026. Vesting for the options occurs over four years, with 25% vesting on the first anniversary of the employee's start date and the remainder vesting in 12 equal quarterly installments, subject to continued service.

The restricted stock units are scheduled to vest over four years from the applicable employee's start date in four equal annual installments, also subject to continued service. These awards are governed by the terms of the award agreements and Dyne's 2024 Inducement Stock Incentive Plan.

Breakdown of Inducement Awards

Dyne Therapeutics has expanded its debt financing capacity to $400 million through an amendment to its senior secured term loan facility with Hercules Capital. The agreement provides an additional $125 million in borrowing capacity, strengthening the company's balance sheet as it advances clinical programs for Duchenne muscular dystrophy and myotonic dystrophy type 1. The increased capital offers strategic flexibility as Dyne prepares for potential U.S. product launches in the next two years.

Under the terms of the amendment, $50 million was funded immediately upon execution. The facility also includes an additional term loan tranche of $50 million, available at Dyne's option subject to achieving specific milestones. Furthermore, the final term loan tranche was increased by $25 million, providing access to an additional $75 million upon request and at Hercules Capital's discretion.

Debt Facility Structure

The amendment modifies the existing loan structure, increasing the total available capital while maintaining secured status. The facility is non-dilutive, allowing Dyne to fund operations without issuing additional equity.

With the $50 million funded at closing, Dyne has drawn an aggregate of $200 million in loan proceeds across three tranches. The company maintains access to the remaining $200 million in potential future funding under the facility.

Erick Lucera, chief financial officer of Dyne, stated that the additional capital enhances financial flexibility for upcoming clinical and regulatory objectives. R. Bryan Jadot, Senior Managing Director at Hercules Capital, affirmed the lender's increased commitment reflects confidence in Dyne's programs.